Return to flip book view
Organizer:Hong Kong Society for HIV Medicine Annual Scientific Meetingcum Chemsex Forum 2024th11 May 2024 (Sat) | 08:30 – 17:00https://www.hkshmasm.comTheme:Advancement in HIV Prevention and Care PROGRAMME BOOK
For today, tomorrow, and the days to comeBIKTARVY® is indicated for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.1 * In clinical trials in treatment-naïve participants, efficacy at Week 48 (primary endpoint) was 91% for BIKTARVY® (pooled [n=634]); efficacy at Week 144 was 82%.2-4 In the optional 96 week open-label extension phase, high rates of virologic suppression were achieved and maintained.5 In clinical trials in virologically suppressed participants, efficacy at Week 48 (primary endpoint) was 94% in Study 1844 (n=282) and 92% in Study 1878 (n=290).6,7 Efficacy defined as viral load <50 copies/mL.2-7 † In clinical studies of treatment-naïve participants receiving BIKTARVY®, the most frequently reported adverse reactions were headache, diarrhoea and nausea.1 At Week 240, <1% (n=5/634) of participants initially randomised to BIKTARVY® discontinued treatment due to TRAEs.8 In clinical studies in virologically suppressed participants, ≤1% of participants discontinued treatment with BIKTARVY® due to adverse events through the open-label extension phase of either study.9,10‡ In pivotal Phase 3 trials, there was 0 treatment-emergent resistance in the final resistance analysis populations.1-10TRAEs=treatment-related adverse events.References: 1. BIKTARVY® Hong Kong prescribing information (HK-AUG21-EU-MAY21). 2. Gallant J, et al. Lancet. 2017;390(10107):2063-2072. 3. Sax PE, et al. Lancet. 2017;390(10107):2073-2082. 4. Orkin C, et al. Lancet HIV. 2020;7(6):e389-e400. 5. Wohl DA, et al. CROI 2022. 12-16 February 2022, virtual. Poster 494. 6. Molina JM, et al. Lancet HIV. 2018;5(7):e357-e365. 7. Daar ES, et al. Lancet HIV. 2018;5(7):e347-e356. 8. Sax P, et al. International AIDS Conference 2022, 29 July–2 August; Montreal, Canada. Poster EPB150. 9. Brar I, et al. Infectious Diseases (ID) Week 2020, 21–25 October. Poster 1028. 10. Rockstroh JK, et al. HIV Glasgow 2020, 5–8 October; Glasgow, UK. Poster 036.Pill not shown at actual size.BIKTARVY® Abbreviated Prescribing Information (Version: HK-AUG21-EU-MAY21) Presentation: Each film-coated tablet contains bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of emtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide. Purplish-brown, capsule-shaped, film-coated tablet debossed with “GSI” on one side and “9883” on the other side of the tablet. Each tablet is approximately 15 mm x 8 mm. Indications: Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Dosage: Adults: One tablet to be taken once daily with or without food. Elderly: No dose adjustment is required. Renal impairment: No dose adjustment for patients with estimated creatinine clearance (CrCl) ≥ 30 mL/min. No dose adjustment is required in adult patients with end stage renal disease (estimated CrCl < 15 mL/minute) who are receiving chronic haemodialysis. Not recommended in patients in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not receiving chronic haemodialysis. Hepatic impairment: No dose adjustment for patients with mild or moderate hepatic impairment (Child-Pugh-Turcotte [CPT] Class A or B). Not recommended in patients with severe hepatic impairment (CPT Class C). Paediatric population: The safety and efficacy in children and adolescents aged less than 18 years not yet been established Contraindications: Hypersensitivity to the active substances or to any of the excipients. Co-administration with rifampicin and St John’s Wort (Hypericum perforatum). Warnings and Precautions: Patients co-infected with HIV and hepatitis B or C virus: Patients with chronic hepatitis B or C treated with HK-BVY-0097_V.1 5/3/2023With up to 5 years’ demonstrated efficacy* and tolerability,† 0 treatment-emergent resistance‡and ≤1% discontinuation in clinical trials,† you can be confident in BIKTARVY® data1-10antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions. Discontinuation of Biktarvy therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis. Patients co-infected with HIV and HBV who discontinue Biktarvy should be closely monitored with both clinical and laboratory follow up for at least several months after stopping treatment. Liver disease: Patients with pre existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. Weight and metabolic parameters: An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Lipid disorders should be managed as clinically appropriate. Mitochondrial dysfunction following exposure in utero: Nucleos(t)ide analogues may impact mitochondrial function to a variable degree. The findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV. Immune Reactivation Syndrome: In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Any inflammatory symptoms should be evaluated and treatment instituted when necessary. Autoimmune disorders have also been reported. Opportunistic infections: Patients should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases. Osteonecrosis: Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement. Nephrotoxicity: A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded. Recommend to assess renal function in all patients prior to, or when initiating, therapy. Monitor renal function during therapy in all patients as clinically appropriate. Co-administration of other medicinal products: Biktarvy should be administered at least 2 hours before, or with food 2 hours after antacids containing magnesium and/or aluminium. Biktarvy should be administered at least 2 hours before iron supplements, or taken together with food. Biktarvy should not be co-administered with other antiretroviral medicinal products. Adverse reactions: Most frequently reported adverse reactions were headache, diarrhoea and nausea. Please refer to full prescribing information for full list of adverse reactions. Drug interactions: Interactions between Biktarvy and other medicinal products: St. John’s wort, rifampicin, rifabutin, rifapentine, atazanavir ± cobicistat, azithromycin, clarithromycin, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, magnesium/aluminium-containing antacid suspension, ferrous fumarate, sucralfate, ciclosporin and metformin.Before prescribing, please consult full prescribing information which is available upon request.BIKTARVY® is a registered trademark of Gilead Sciences, Inc., or its related companies.For medical enquiries, please send your request to asiamedinfo@gilead.com or call 800 908 348 (toll-free number).Gilead Sciences Hong Kong LimitedRoom 2603, 26/F, Hysan Place, 500 Hennessy Road,Causeway Bay, Hong KongTel: +852 3129 2000 Fax: +852 2856 2611
Table of Contents3General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4About Hong Kong Society for HIV Medicine (HKSHM). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5Message from Society President. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10Introduction of Speakers (Chemsex Forum 2024). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Introduction of Open Forum’s Conveners. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18Introduction of Speakers (HKSHM Annual Scientific Meeting) . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Acknowledgement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4General InformationCONFERENCE LANGUAGEChemsex Medical Forum 2024 - it will be executed in Chinese.HKSHM Annual Scientific Meeting - it will be executed in English.CERTIFICATE OF ATTENDANCEAfter fully completed the live conference, a certificate of attendance will be sent to your registered email automatically.CONTINUING MEDICAL EDUCATION (CME)CONTINUING NURSING EDUCATION (CNE)For CME / CNE accreditation purposes, a simple quiz and a meeting evaluation survey, in a multiple-choice format, will be sent to your registered email within 48 hours after the meeting. If you cannot receive our email, please email to enquiry@bestsolution.com.hk or call 3954 5301 for assistance.DISCLAIMERWhilst every effort will be made to ensure that the Conference will take place as described in the programme, the Organizing Committee reserves the right to change the programme and related arrangements without prior notice as and when deemed necessary.The presentations or information provided by speakers and moderators at the Conference represent their personal opinions and do not necessarily represent those of the Conference or its organizers. The Conference and its organizers shall not be held liable for any errors, omissions, misstatements or misrepresentations, whether expressed or implied, of any information shared at the Conference.PROHIBITIONWe kindly remind all attendees that the presentations and videos shown during the Conference are strictly prohibited from being captured or photographed under any circumstances. Unauthorized reproduction or distribution of this content is strictly prohibited. Thank you for your cooperation in respecting this policy.
5About HKSHMThe Hong Kong Society for HIV Medicine (HKSHM) was incorporated in October 2016 with the following objectives:• To advance knowledge and the practice of HIV medicine• To promote sharing and exchanges in the practice of HIV medicine• To advocate for quality HIV care and prevention• To disseminate research result to the public and promote training on HIV/AIDSHong Kong Society for HIV Medicine Council (2023-2025)PresidentDr. WONG Chun Kwan, BonnieVice-PresidentDr. CHAN Man Chun, JackyHonorary SecretaryDr. KWONG Tsz ShanHonorary TreasurerDr. HUI Wai ManWebsite: www.hivmed.hkE-mail: hkshm2016@gmail.comCouncil MembersDr. CHAN Jun Yi, AbramDr. CHENG Shui Kuen, LilyDr. CHU Man YeeDr. HO Po Ki, PollyDr. KWAN Chi KeungDr. LAM Kwok WaiDr. LAM WilsonDr. LEE Chi Kei, KrystalDr. LEE Man PoDr. LEUNG Wai ShingDr. LIN Wai Chi, AdaDr. LUI Chung Yan, GraceDr. SIT Yao Wai, AlfredDr. TO Ki Wai, HeatherDr. TSANG Tak Yin, OwenHong Kong Society for HIV Medicine Limited ( 香港愛滋病醫學會有限公司) is confirmed by the Inland Revenue Department with effect from 8 May 2018 to be a charitable institution and is exempt from tax. (IR file number 91/15538)
7Message from Society PresidentDear guests, friends and colleagues,On behalf of the Hong Kong Society for HIV Medicine, I am honoured to welcome you to our7th Annual Scientic Meeting (ASM) that has resumed face-to-face after running virtual forthree consecutive years.Our theme for this ASM is “Advancement in HIV Prevention and Care” and we have broughttogether overseas and local distinguished speakers to share with us the different areas ofadvancement along the HIV prevention and care continuum, including prevention strategiesfor people at risk of HIV acquisition, the challenges of linking people to the prevention andtreatment pathway, the use of newer antiretrovirals in our treatment armamentarium thathelps us achieve the fourth 95, and prevention of mother-to-child transmission of HIV,though rare, but remains highly relevant in our locality.We are also immensely grateful to have the opportunity to co-organise the Chemsex Forum2024 with the Hong Kong Advisory Council on AIDS. Chemsex has evolved to be aninternational public health concern over the past 2 decades. It has become more widelypracticed and has led to unwanted consequences in not only physical and sexual health withincreased risks of acquisition of HIV and other sexually transmitted infections, but also inmental health and social wellbeing of individuals practicing it. Frontline healthcare andcommunity workers have witnessed a rising trend in the number of problematic users, whohave been experiencing different level of challenges during their journey of seekingassistance. It is hoped that through this Chemsex Forum, we can bring together healthcareproviders, researchers, therapists, service providers and chemsex responders from all walksto update on the current landscape of chemsex in Hong Kong, to discuss the challengesfaced by people suffering from its problematic use, to introduce to the audience the existingresources that are available for people seeking help, and to explore opportunities forestablishing more robust interdisciplinary collaborations to more appropriately andeffectively respond to the emerging needs of service users.I sincerely thank you all for your participation in this ASM cum Chemsex Forum and hope weall have a fruitful learning and networking experience.Dr. Bonnie Chun-Kwan WONGPresidentHong Kong Society for HIV MedicineDr. Bonnie Chun-Kwan WONG
9Floor Plan
10ProgrammeChemsex Forum 2024 – Hong Kong (co-organised with HK Advisory Council on AIDS)08:30 – 09:00Registration09:00 – 09:10Opening remarksDr. King-Man HO Chairman, Hong Kong Advisory Council on AIDSDr. Bonnie Chun-Kwan WONG President, Hong Kong Society for HIV MedicineChaired by Dr. Jacky CHAN and Dr. Man-Po LEE09:10 – 09:35The current chemsex landscape in Hong Kong(includes 5 mins Q&A)Dr. Candy WONG Stanley Ho Centre for Emerging Infectious Diseases,The Chinese University of Hong Kong09:35 – 10:10Are we failing? A call for concerted responses to chemsex(includes 5 mins Q&A)Dr. Krystal LEEDepartment of Psychiatry, LKS Faculty of Medicine,The University of Hong Kong10:10 – 10:35Application of motivational interviewing in chemsex(includes 5 mins Q&A)Dr. Katherine LAMSchool of Nursing, The Hong Kong Polytechnic University10:35 – 11:00Postmodern psychology of chemsex: clinical or not?(includes 5 mins Q&A)Dr. Barry TAM Clinical Psychologist11:00 – 11:20Tea BreakChaired by Dr. Grace LUI and Dr. Bonnie WONG11:20 – 11:40Community work in Singapore Dr. Rayner TANSociety of Behavioural Health, Singapore11:40 – 12:20Open forum: “What can we do together? Whole-of-society approach for a people-centred response”Conveners: Dr. Bonnie WONG, Dr Krystal LEE, Dr. Sam LI and Mr. Samson YIP
11ProgrammeHong Kong Society for HIV Medicine Annual Scientific Meeting12:20 – 12:45Registration12:45 – 12:55Welcome SpeechDr. Bonnie Chun-Kwan WONG President, Hong Kong Society for HIV MedicineChaired by Dr. Abram CHAN and Dr. Wyman HUI12:55 – 14:10Lunch Symposium:Access to ART and strategy in preventing HIV in high-risk population (includes 15 mins Q&A)Dr. Jason ONGMelbourne Sexual Health Centre, Monash University, Australia14:10 – 14:55A step forward in HIV treatment as prevention: real-world evidence sharing on the 1st long-acting regimen(includes 10 mins Q&A)Dr. Jan BORCHMVZ Goldstein GMBH, Germany14:55 – 15:15Tea Break (AGM)Chaired by Dr. Lily CHENG and Dr. Ruby Tsz-Shan KWONG15:15 – 16:00Prevalence and clinical impact of NNRTI resistance mutations in real-world populations of NNRTI-Naive and NNRTI-Experienced individuals (includes 10 mins Q&A) Dr. Chanson BRUMMEBritish Columbia Centre for Excellence in HIV/AIDS, Canada16:00 – 16:45Prevention of mother-to-child transmission of HIV and the local perspective(includes 10 mins Q&A) Dr. Polly Po-Ki HOSpecialist in Paediatric Immunology Allergy and Infectious DiseasesDr. Ruby Tsz-Shan KWONG Specialist in InfectiousDiseasesClosing remarksDr. Jacky Man-Chun CHAN Vice-President, Hong Kong Society for HIV Medicine
12
Introduction of Speakers13The current chemsex landscape in Hong KongDr. Candy WONGS.H. Ho Research Centre for Infectious Diseases,The Chinese University of Hong KongBiography:Dr. Candy WONG is an Assistant Professor of S.H. Ho Research Centre for Infectious Diseases, JC School of Public Health and Primary Care, the Chinese University of Hong Kong (CUHK). She holds a BSSc and a M.Phil degree in Geography and Resource Management, and a PhD degree in Public Health from CUHK. She received training in a joint China-US postdoc programme, staying in Guangzhou, China and the University of North Carolina at Chapel Hill in the United States. She was the principal investigator (PI) of a few HIV research projects, such as HIV pre-exposure prophylaxis (PrEP) implementation study, chemsex engagement cross-sectional study, and cost-effectiveness analysis for latent TB infection screening strategies in people in HIV care. She is the PI of sexually transmitted infection (STI) epidemiology projects, and HBV and HCV epidemic modelling projects in Hong Kong. She has published 100 articles in peer-reviewed journals, and is currently a journal editorial board member of Infectious Diseases.
Introduction of Speakers14Are we failing? A call for concerted responses to chemsexDr. Krystal LEEDepartment of Psychiatry, LKS Faculty of Medicine,The University of Hong KongBiography:Dr. Krystal LEE is a specialist psychiatrist and a fellow in community medicine. Prior to her psychiatric training, she worked on HIV prevention and surveillance in the Department of Health, and on community-based HIV epidemiology studies in the Chinese University of Hong Kong. One area of her current clinical work and research is related to chemsex, which touches upon mental health, sexuality, substance use, and HIV care. She is providing consultations in the Queen Mary Hospital and Kowloon Bay Integrated Treatment Centre.
Introduction of Speakers15Application of motivational interviewing in chemsexDr. Katherine LAMSchool of Nursing,The Hong Kong Polytechnic UniversityBiography:Dr. Katherine LAM is a registered nurse who graduated from the University of Hong Kong. She is currently the assistant professor in School of Nursing, the Hong Kong Polytechnic University. Her research expertise focuses on various counselling and nursing interventional studies for addictive behaviours including smoking, alcohol use, drug abuse, and internet addiction. Particularly, she is the co-principle investigator of Youth Quitline for over 5 years. It is the ofcial counselling hotline funded by Department of Health, HKSAR, to train nursing students with motivational interviewing to provide free smoking cessation counselling to young smokers aged 25 or below.She has also worked with Tobacco and Alcohol Control Unit in Department of Health (TACO), HKSAR to provide annual workshops of motivational interviewing on smoking cessation to healthcare professionals in Hong Kong. She has also turned the workshops into an online training posted on the TACO website for all healthcare professionals. She is also the treasurer in Community Health Organization for Intervention, Care and Empowerment, which is a non-governmental organisation promoting disease prevention in the community including people suspected with or diagnosed with HIV.
Introduction of Speakers16Postmodern psychology of chemsex: clinical or not?Dr. Barry TAMClinical PsychologistBiography:Dr. Barry TAM is a clinical psychologist working in a local public hospital, having served people living with HIV (PLWH) since 2016. He received his clinical training at University College London, which has a long history of ghting for equality. Barry is a keen advocate of awareness of HIV-associated neurocognitive disorder (HAND) and ageing with HAND. Promoting hospital-community partnerships, Barry has been involved in HIV-related awareness raising activities for staff and service users in local charities since 2019. In treatment, Barry’s work with PLWH was greatly inuenced by ideas from narrative therapy, which advocates the understanding of self as a product through relationships. Barry often questions the process by which people come to describe and explain the world. He invites PLWH to negotiate relationships with themselves and others, especially challenging the discourses of stigma that might have come to dominate their life stories. Barry started the rst psychological screening clinic for PLWH attending public hospital in 2017; particularly, this involves identifying and working with people facing disclosure issues given HIV-related stigma. Apart from providing support at the individual level, he was inspired to join Hong Kong AIDS Foundation as an executive board member. Barry also awarded the Champion of IAS Me and My Healthcare Provider 2022.
Introduction of Speakers17Community work in SingaporeDr. Rayner TANSociety of Behavioural Health, SingaporeBiography:Dr. Rayner Kay Jin TAN (he/him) is an Assistant Professor at the Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, where he received his PhD. He is also a visiting research fellow at the National Centre for Infectious Diseases, Singapore. His research revolves broadly about the social determinants of health, community engagement, implementation science, and health equity of vulnerable communities. He is the research and behavioural lead at HeHealth.ai and also leads several non-prot organisations in Singapore, including the Society of Behavioural Health Singapore, The Greenhouse Community Services (substance use and addiction recovery), Project X Singapore (sex workers’ rights and welfare), and SG Mental Health Matters (mental health policy advocacy).
Introduction of Open Forum’s Conveners18Open forum: “What can we do together? Whole-of-society approach for a people-centred response”Dr. Bonnie Chun-Kwan WONGPresident, Hong Kong Society for HIV MedicineBiography:Dr. Bonnie Chun-Kwan WONG is an infectious disease specialist and is currently an HIV physician in one of the public HIV clinics in Hong Kong. She rst learned about chemsex in 2015 and kept gaining her perspectives in this area through learning from her clients who have selessly shared their ups and downs along their chemsex journey with her.Dr. Krystal Chi-Kei LEEDepartment of Psychiatry, LKS Faculty of Medicine,The University of Hong KongBiography:Dr. Krystal Chi Kei LEE is a specialist psychiatrist and a fellow in community medicine. Prior to her psychiatric training, she worked on HIV prevention and surveillance in the Department of Health, and on community-based HIV epidemiology studies in the Chinese University of Hong Kong. One area of her current clinical work and research is related to chemsex, which touches upon mental health, sexuality, substance use, and HIV care. She is providing consultations in the Queen Mary Hospital and Kowloon Bay Integrated Treatment Centre.
Introduction of Open Forum’s Conveners19Dr. Sam Wing-Sum LI Trainee, Community Medicine (Public Health Medicine)Mr. Samson Wing-Yue YIPRegistered Social WorkerBiography:Dr. Sam Wing-Sum LI is a trainee in Community Medicine (Public Health Medicine). He was a research intern at World Health Organization Health Systems Cluster (Geneva), as well as United Nations Relief and Works Agency for Palestine Refugees (Amman). Dr. Li obtained his MBChB degree in CUHK, and LLM (Technology and Intellectual Property Law) in HKU. Currently, he is studying part time to pursue MSc in Global Health Policy at LSHTM. He volunteers at the Hong Kong LGBT Medical Society and recently conducted needs assessment on LGBTQIA+ health promotion.Biography:Mr. Samson Wing-Yue YIP is a registered social worker and currently serves as the Service Supervisor at PS33 Tsimshatsui Centre, HKCS. He is dedicated to supporting MSM who are engaged in chemsex. In 2017, he established Project HERO-MSM Support Service, which continues to provide targeted assistance to this community.
Introduction of Speakers20Lunch Symposium: Access to ART and strategy in preventing HIV in high-risk populationDr. Jason ONGMelbourne Sexual Health Centre,Monash University,AustraliaBiography:Dr. Jason ONG is an academic sexual health physician and health economist. He graduated with a PhD from the University of Melbourne and now is an associate professor in Monash University. He is the current recipient of a prestigious Australian National Health and Medical Research Emerging Leadership Fellowship. His post-doctoral study focused on economic evaluations and demand creation strategies for improving HIV and sexually transmitted infection (STI) outcomes among vulnerable populations (e.g. MSM, adolescents, transgender populations). Dr. Ong also has over 300 publications in peer-reviewed journals and book chapters.
Introduction of Speakers21A step forward in HIV treatment as prevention: real-world evidence sharing on the 1st long-acting regimenDr. Jan BORCHMVZ Goldstein GMBH, GermanyBiography:Dr. Jan BORCH is a specialist in HIV medicine based in Berlin, Germany. In addition to his expertise in HIV medicine, he is qualied in internal medicine and psychotherapy. He currently practices at MVZ Goldstein, an outpatient clinic in Berlin. Dr. Borch graduated from the Charité - Universitätsmedizin Berlin in 2005. He began his professional career at the University Hospital Münster, followed by a period at the University Hospital Hamburg-Eppendorf. Since 2018, he has been dedicated to providing outpatient HIV care in Berlin.
Introduction of Speakers22Prevalence and clinical impact of NNRTI resistance mutations in real-world populations of NNRTI-Naive and NNRTI-Experienced individualsDr. Chanson BRUMMEBritish Columbia Centre for Excellence in HIV/AIDS,CanadaBiography:Dr. Chanson BRUMME is an Assistant Director of the Research Laboratories at the BC Centre for Excellence in HIV/AIDS . Dr. Brumme completed his PhD in Experimental Medicine at the University of British Columbia and has trained at the Ragon Institute of MGH, MIT and Harvard, the Broad Institute and Microsoft Research. In his role at the BC-CfE Laboratory - which is accredited by the Diagnostic Accreditation Program of the College of Physicians and Surgeons of British Columbia, the College of American Pathologists and is a WHO-designated Specialized HIV Drug Resistance Testing Laboratory - Dr. Brumme is responsible for directing the delivery of genotypic drug resistance testing for HIV and HCV, pharmacogenomic screening and therapeutic drug level monitoring of antiretrovirals for clients in British Columbia and across Canada.
Introduction of Speakers23Prevention of mother-to-child transmission of HIV and the local perspectiveDr. Polly Po-Ki HOSpecialist in Paediatric Immunology Allergy and Infectious Diseases Biography:Dr. Polly Po-Ki HO is Associate Consultant of the Department of Paediatrics, Queen Elizabeth Hospital. She obtained her medical degree at the University of Hong Kong. She received subspecialty training in paediatric infectious disease, allergy and immunology at Queen Elizabeth Hospital, Hospital Authority Infectious Disease Centre at Princess Margaret Hospital and Prince of Wales Hospital. She received overseas subspecialty training in paediatric infectious disease and immunology at Great Ormond Street Hospital for Children under Prof. Nigel Klein and Dr. Delane Shingadia, and St Mary’s Hospital, London under Prof. Mike Levin. She is an accredited subspecialist in Paediatric Immunology Allergy and Infectious Diseases of the Hong Kong College of Paediatricians.Dr. Ho obtained Postgraduate Diploma in Infectious Diseases and Master of Medical Science from the University of Hong Kong, Postgraduate Diploma in Epidemiology and Statistics and Master of Public Health from the Chinese University of Hong Kong. She has been a Council Member of the Hong Kong Society for Paediatric Immunology Allergy and Infectious Diseases since 2016. She also serves as Honorary Clinical Assistant Professor in the Department of Paediatrics and Adolescent Medicine of the University of Hong Kong and the Department of Paediatrics of the Chinese University of Hong Kong.
Introduction of Speakers24Prevention of mother-to-child transmission of HIV and the local perspectiveDr. Ruby Tsz-Shan KWONGSpecialist in Infectious Diseases Biography:Dr. Ruby Tsz-Shan KWONG is a Specialist in Infectious Diseases and HIV medicine. She obtained her medical degree at the University of Hong Kong, and Master of Science in Epidemiology and Biostatistics at the Chinese University of Hong Kong. Her academic and research interests include HIV in women and HIV in aging population. She is the leading physician of a women’s HIV clinic of a tertiary referral centre, offering multidisciplinary care to women living with HIV. She is currently a Council Member of the Hong Kong Society for HIV Medicine.
25AcknowledgementSponsors
Hong Kong Society for HIV Medicine Annual Scientific Meetingcum Chemsex Forum 2024thTheme:Advancement in HIV Prevention and Care